CAI vs GH
CAI: Caris Life Sciences delivers comprehensive molecular profiling and precision medicine insights to optimize oncology treatment and drug development. GH: Guardant Health is a leader in precision oncology, utilizing advanced liquid biopsy technology to provide comprehensive genomic insights across the cancer care continuum.
Side-by-side fundamentals
| Metric | CAI | GH | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $27.50 | $165.56 | |
| Market cap | $7.8B | $22.2B | |
| P/E as of 2026-10-08 | 74.97 | n/a | |
| Net margin FY2025, SEC XBRL | -8.4% | -42.4% | CAI higher |
| Operating margin FY2025, SEC XBRL | +5.6% | -44.5% | CAI higher |
| ROE FY2025, SEC XBRL | -11.8% | n/a | |
| ROA FY2025, SEC XBRL | -6.0% | -20.7% | CAI higher |
| Debt / equity as of 2026-09-03 | 0.66 | 16.78 | CAI lower |
| Revenue growth (YoY) as of 2026-09-03 | +38.5% | +42.7% | GH higher |
| Revenue CAGR (3y) SEC XBRL | +62.9% | +29.8% | CAI higher |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-03 | 1.27 | 1.23 | |
| 1-year return as of 2026-10-08 close | -16.5% | +153.5% | GH higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.